Results 111 to 120 of about 129,762 (268)

New approaches to treating chronic obstructive pulmonary disease with Colla corii asini

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Colla corii asini improves chronic obstructive pulmonary disease (COPD) treatment through anti‐inflammatory, antioxidant, immune‐modulatory, and lung‐nourishing effects, addressing current therapeutic challenges via multitarget mechanisms. Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability ...
Wenchao Zhang   +5 more
wiley   +1 more source

Engineering Ultrasound Contrast Agents for Targeted Therapeutics: A Theranostic Approach to Drug Delivery, Gene Therapy, and Immunomodulation

open access: yesAdvanced NanoBiomed Research, EarlyView.
Ultrasound contrast agents, including microbubbles and nanobubbles, transform imaging and targeted therapy through precise engineering of size, shell composition, and surface properties. This review explores how these innovations enable tissue‐specific delivery, enhance therapeutic efficacy, and extend applications from vascular imaging to tumor ...
Ashkan Seza   +2 more
wiley   +1 more source

Engineering Tertiary Lymphoid Structures: Nanomedicine, Bioengineering, and Biomaterials for Precision Immunotherapy

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley   +1 more source

Multi‐Omics Insights Into the Role of Fructooligosaccharides Supplementation in Alleviating Salpingitis in Laying Hens

open access: yesAnimal Research and One Health, EarlyView.
Multi‐omics analysis revealed that FOS supplementation increased the abundance of Phascolarctobacterium, GCA‐900066575, Shuttleworthia, Olsenella, Eubacterium_hallii_group while decreasing Alistipes. It also influenced the metabolism of S‐lactoylglutathione, p‐cresol glucuronate, 2‐phenylethanol glucuronide, propionic acid, dulcitol, and inhibited the ...
Dan Song   +11 more
wiley   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

open access: yesArthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek   +7 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

Family history of pulmonary fibrosis impacts prognosis in patients with sarcoidosis

open access: yesERJ Open Research
Thomas Planté-Bordeneuve   +6 more
doaj   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy